Ventas, Inc. research snapshot
VTR AI stock analysis currently reads Ventas as a leading healthcare REIT tied to the longevity economy, with more than 1,400 properties, about 900 senior housing communities, outpatient medical and research assets, and triple-net healthcare properties. The July 8, 2026 setup is supported by strong SHOP same-store cash NOI growth, improving leverage, rising 2026 normalized FFO guidance, and a bullish chart. The investment case is still not a simple buy signal because the stock has rerated toward a 52-week high, GAAP earnings remain low relative to price, and the business is exposed to interest rates, senior housing labor costs, operator execution, equity issuance, and healthcare real estate cycles.
Current price
$93.18 intraday reference
Market cap
$45.62 billion verified market cap
AI score
68 / 100
Rating
High-quality healthcare REIT with strong senior housing growth, improving leverage, and valuation sensitivity after a large rerating
Trend status
Uptrend, above the 50-day and 200-day moving averages with positive but watchful momentum
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Ventas owns senior housing, outpatient medical, research, and healthcare real estate assets that benefit from aging demographics, healthcare demand, and property-level operating improvement. | High |
| Moat | Scale, location quality, operator relationships, healthcare real estate expertise, data-driven Ventas OI initiatives, and access to capital support the moat, but REIT assets are capital intensive and rate sensitive. | Medium-high |
| Management | Debra Cafaro has led a long-running healthcare REIT platform and is now pushing senior housing investment growth while improving net debt to Further Adjusted EBITDA to 5.0x. | Medium-high |
| Financial trend | FY2025 total revenue was $5.83 billion and FY2025 net income was $261.5 million. Q1 2026 revenue rose to $1.66 billion, with normalized FFO per share up 9% year over year to $0.94. | High |
| Valuation | At $93.18, VTR screens near 169x TTM EPS, 3.45x book value, negative free cash flow per share under StockAnalysis cash-flow data, and a 2.23% dividend yield. | High |
| Technical trend | The stock trades near a 52-week high and above moving averages. Investing.com showed a 50-day average near $89.18, a 200-day average near $84.99, and RSI near 63.4. | Medium |
| Risk level | Main risks are higher rates, equity dilution, senior housing labor inflation, weaker occupancy, operator or tenant stress, healthcare reimbursement pressure, and paying too much for recovery growth. | Medium-high |
| AI confidence | Descriptive confidence is high because filings and third-party data align. Return confidence is lower because REIT multiples can reset quickly when rates or capital-market conditions change. | High data confidence |
| Investment certainty | VTR is a strong healthcare REIT platform, but the current price needs continued SHOP growth, successful external investment, and stable rates to justify the rerating. | Medium |
VTR AI stock forecast
The VTR AI stock forecast is scenario-based because Ventas depends on senior housing occupancy, RevPOR, labor costs, cap rates, interest rates, equity funding, leverage, and FFO growth. Using the $93.18 price reference, TTM EPS of $0.55, and the audited three-year EPS model, the mechanical range points to about $33 in a bear case, $92 in a base case, and $193 in a bullish case. For REITs, normalized FFO and asset value often matter more than GAAP EPS, so the model is a stress-test framework rather than a target promise.
$115 to $150 before dividends
More likely if SHOP same-store cash NOI keeps growing at a double-digit pace, occupancy and RevPOR stay firm, 2026 normalized FFO per share moves above guidance, leverage improves, and long rates do not pressure REIT multiples.
$85 to $105 before dividends
More likely if VTR delivers guidance, senior housing growth offsets higher funding costs, acquisitions are accretive, and the market values the company near current healthcare REIT multiples without a major rate shock.
$55 to $75 before dividends
More likely if rates rise, equity issuance becomes dilutive, labor costs squeeze SHOP margins, tenant or operator stress returns, occupancy growth slows, or investors reprice VTR closer to lower-growth REITs.
VTR AI technical analysis
VTR AI technical analysis is positive but extended as of the July 8, 2026 data cutoff. StockAnalysis showed a $93.18 intraday reference and a 52-week range of $62.06 to $94.60. Investing.com technical data showed the stock above its 50-day moving average near $89.18 and 200-day moving average near $84.99, with RSI near 63.4. That supports an uptrend, but the stock is close enough to its high that support and invalidation levels matter.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $93.18 intraday | StockAnalysis listed this July 8, 2026 intraday reference during market hours. |
| Immediate support | $90 to $92 | This range brackets the recent breakout and July 2 close near $92.52, where volume was above the 50-day average. |
| Trend support | $88 to $90 | This range sits near the 50-day moving average reported around $89.18. |
| Long-term support | $83 to $85 | This range brackets the 200-day moving average near $84.99 and is a deeper trend-risk review zone. |
| Near resistance | $94.60 to $97 | The 52-week high near $94.60 and analyst average target near $96.73 create the first resistance band. |
| Upper resistance | $105 to $115 | This is a scenario zone, not a target promise. It likely requires stronger FFO guidance, steady rates, and continued SHOP acceleration. |
| Moving averages | 50-day near $89.18, 200-day near $84.99 | Trading above both averages supports the current uptrend. A close below the 50-day average would reduce trend confidence. |
| Momentum | RSI near 63.4 | Momentum is positive but not yet at an extreme overbought reading, so price can keep trending if fundamentals confirm. |
| Volume | July 2 volume near 5.4 million shares | MarketWatch reported July 2 volume above the 50-day average, which supports breakout confirmation but can also mark crowded short-term buying. |
| Volatility | Watch July 29, 2026 earnings | The next earnings release, rate moves, senior housing occupancy, acquisition funding, and FFO guidance are likely volatility drivers. |
| Invalidation | Close below $88, then below $84 | A sustained break below the 50-day zone weakens the trend. A break below the 200-day zone would challenge the larger uptrend. |
VTR AI trading strategy
The VTR AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with senior housing NOI, occupancy, RevPOR, labor costs, interest rates, net debt to EBITDA, dividend coverage, acquisition funding, and FFO guidance.
Watch for VTR to hold the $90 to $92 breakout area and keep trading above the 50-day average while Q2 earnings confirm SHOP growth, FFO guidance, liquidity, and leverage improvement.
A close below $88 should reduce trend confidence, especially if management signals weaker occupancy, higher labor costs, less accretive acquisitions, or higher funding costs.
If VTR pulls back toward the $83 to $85 long-term support zone without a break in senior housing demand or balance-sheet stress, compare the lower price with normalized FFO, dividend coverage, and asset value.
Do not treat a pullback as attractive if higher rates compress REIT valuations, SHOP margins deteriorate, tenants weaken, or equity issuance is needed at unfavorable prices.
Track SHOP same-store cash NOI, occupancy, RevPOR, labor expense, 2026 normalized FFO per share, net debt to Further Adjusted EBITDA, liquidity, acquisitions, cap rates, dividend growth, and 10-year Treasury yields.
Position sizing should reflect that Ventas is a high-quality but rate-sensitive REIT, not a guaranteed income stock or a precise AI price prediction.
Investment research summary
Customers and tenants pay Ventas because seniors, healthcare providers, universities, research users, and operators need specialized real estate in attractive markets. The business converts healthcare property ownership, operating partnerships, and capital allocation into rent, resident fees, NOI, FFO, and dividends.
Ventas has scale, a large senior housing base, outpatient medical and research assets, operator relationships, healthcare real estate expertise, data-driven operating insights, and access to public capital. The moat is meaningful, but it can narrow if rates rise, operators struggle, or replacement capital becomes expensive.
The thesis fails if the market overpays for a cyclical senior housing recovery, labor costs offset occupancy gains, new equity dilutes holders, higher rates pressure cap rates, or tenant and operator stress damages cash flows.
Debra Cafaro has built one of the larger healthcare REIT platforms and is now emphasizing senior housing growth, Ventas OI, liquidity, leverage improvement, and dividend growth. The current test is disciplined capital allocation after a strong stock rerating.
Aging demographics, senior housing demand, outpatient care, and healthcare research support a long-term longevity economy trend. The offset is that real estate returns still depend on rates, labor, construction supply, reimbursement, operator health, and capital markets.
At $93.18, VTR prices in a large portion of the recovery. Margin of safety improves if normalized FFO grows above guidance or if the stock pulls back while SHOP growth, leverage, liquidity, and dividend coverage remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| VTR quote reference | $93.18 intraday on July 8, 2026 | StockAnalysis VTR financials | July 8, 2026 |
| Market capitalization verification | $45.62 billion reported and $45.62 billion calculated from $93.18 x 489.61 million shares | Pineify financial_rigor.py and StockAnalysis VTR overview | July 8, 2026 |
| Shares outstanding | 489.61 million shares outstanding, up 10.67% year over year | StockAnalysis VTR statistics | July 8, 2026 |
| FY2025 revenue | $5.83 billion total revenue, cross-checked against Macrotrends and StockAnalysis | Ventas FY2025 results | July 8, 2026 |
| FY2025 net income | $261.5 million net income and $251.4 million net income attributable to common stockholders | Ventas FY2025 results | July 8, 2026 |
| Q1 2026 earnings | $1.66 billion revenue, $55.9 million net income attributable to common stockholders, $0.90 Nareit FFO per share, and $0.94 normalized FFO per share | Ventas Q1 2026 results | July 8, 2026 |
| Q1 2026 balance sheet and liquidity | $183.6 million cash, $12.52 billion senior notes payable and other debt, $5.5 billion liquidity, and 5.0x net debt to Further Adjusted EBITDA | Ventas Q1 2026 results | July 8, 2026 |
| Q1 2026 operating drivers | SHOP same-store cash NOI increased more than 15%, same-store cash operating revenue grew nearly 9%, and total SHOP same-store average occupancy rose 310 basis points | Ventas Q1 2026 results | July 8, 2026 |
| 2026 guidance | Attributable net income per share guidance of $0.56 to $0.63, Nareit FFO per share of $3.69 to $3.76, and normalized FFO per share of $3.82 to $3.89 | Ventas Q1 2026 results | July 8, 2026 |
| Technical and valuation snapshot | 171.88 PE, 141.91 forward PE, 2.23% dividend yield, 50-day moving average near $89.18, 200-day moving average near $84.99, and RSI near 63.4 | StockAnalysis and Investing.com VTR technical data | July 8, 2026 |
This VTR AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 8, 2026, and can be wrong if rates, senior housing demand, labor costs, operator performance, capital markets, or REIT valuation multiples change.
